




RealRate

PHARMACEUTICAL 2022

KIORA PHARMACEUTICALS INC
Rank 398 of 475



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2022

KIORA PHARMACEUTICALS INC Rank 398 of 475



The relative strengths and weaknesses of KIORA PHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of KIORA PHARMACEUTICALS INC compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 230% points. The greatest weakness of KIORA PHARMACEUTICALS INC is the variable Net Income, reducing the Economic Capital Ratio by 214% points.

The company's Economic Capital Ratio, given in the ranking table, is -421%, being 144% points below the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	8,991
Cost of Goods Sold	0
Intangible Assets	8,696
Liabilities, Current	1,610
Liabilities, Non-Current	7,224
Other Assets	297
Other Compr. Net Income	-86
Other Expenses	5,964
Other Liabilities	0
Other Net Income	243
Property and Equipment	74
Research and Development	5,350
Revenues	0
Selling, General and Administrative Expense	5,324

Output Variable	Value in 1000 USD
Assets	18,058
Liabilities	8,833
Expenses	16,638
Stockholders Equity	9,225
Net Income	-16,395
Comprehensive Net Income	-16,438
Economic Capital Ratio	-421%

